The Usefulness of Preoperative 18FDG Positron-Emission Tomography and Computed Tomography for Predicting the Malignant Potential of Gastrointestinal Stromal Tumors

Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. The tumor size and mitotic count, typical risk category factors, are difficult to determine preoperatively. This study aimed to evaluate the usefulness of preoperative 18F-fluoro-2-deoxyglucose positron-emission tomography/computed tomography (18FDG-PET/CT) for predicting the malignant potential of GISTs by analyzing the correlation between the maximum standardized uptake value (SUVmax) and postoperative factors. Methods: Thirty consecutive patients underwent surgery after preoperative 18FDG-PET/CT and were diagnosed with pathologically confirmed GIST. The tumor size, mitotic count, MIB-1 index and National Institutes of Health (NIH) risk category were compared with SUVmax. Results: Significant correlations between SUVmax and tumor size and NIH risk category were determined. The sensitivity and specificity of SUVmax for predicting the risk of malignancy were 85.7 and 62.5%, respectively. The optimal cut-off value for SUVmax was 3.0 between patients classified into low-risk and high-risk malignancy groups. There was no significant correlation between SUVmax and mitotic count or MIB-1 index. Multivariate analysis indicated that SUVmax was the only predictive risk factor in the high-risk malignancy group. Conclusions: 18FDG-PET/CT is useful for assessing the malignant potential and bioactivity of GISTs. When SUVmax is >3.0, the tumor must be resected even if it measures <2 cm, because of its high malignant potential.

[1]  M. Shimada,et al.  The efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors , 2013, Surgery Today.

[2]  Hyundong Chae,et al.  Role of 18F-fluoro-2-deoxyglucose Positron Emission Tomography in Gastric GIST: Predicting Malignant Potential Pre-operatively , 2011, Journal of gastric cancer.

[3]  M. Harada,et al.  Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors. , 2010, The journal of medical investigation : JMI.

[4]  S. Hirota,et al.  Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version , 2008, International Journal of Clinical Oncology.

[5]  J. Fletcher,et al.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Crowley,et al.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Antonescu,et al.  Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor , 2007, Annals of surgery.

[8]  Y. Hirooka,et al.  Gastric GIST malignancy evaluated by 18FDG-PET as compared with EUS-FNA and endoscopic biopsy , 2007, Scandinavian journal of gastroenterology.

[9]  H. Kuwano,et al.  18F-Fluorodeoxyglucose Positron Emission Tomography: Useful Technique for Predicting Malignant Potential of Gastrointestinal Stromal Tumors , 2005, World Journal of Surgery.

[10]  J. Blay,et al.  Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  D. Brewster,et al.  Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach , 2003, Histopathology.

[12]  Y. Nakanishi,et al.  Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients , 2003, Gastric Cancer.

[13]  C. Fletcher Clinicopathologic correlations in gastrointestinal stromal tumors. , 2002, Human pathology.

[14]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[15]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[16]  G. Demetri,et al.  Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665 , 2009, Journal of surgical oncology.

[17]  金子 文成,et al.  長時間歩行時の下肢筋の活動状態:[ 18 F]fluorodeoxyglucoseを用いたPositron Emission Tomographyによる検討 , 2008 .

[18]  J. Lasota,et al.  Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.

[19]  S. Hirota,et al.  Molecular pathology of c-kit proto-oncogene and development of gastrointestinal stromal tumors. , 1998, Annales chirurgiae et gynaecologiae.